

21 April 2023

BSF Enterprise PLC
("BSF" or the "Company")

Showcase Meat Update

BSF Enterprise plc (LSE: BSFA), a company focused on unlocking the next generation of biotech solutions, is pleased to announce that its wholly owned subsidiary, 3D Bio-Tissues (3DBT), is making positive progress in relation to the development of its products and is on track to produce and display the full-scale 100% meat fillet of cultivated pork, as well as a series of 100% new meat strips of cultivated pork, which will be showcased before the end of H1 2023.

In producing these fillets and strips, the team is building on the technical findings and data collected from the development of the Company's first full-scale fillet, as announced in January 2023. Once produced, the products will undergo testing at a technical event organised by the Company, to which key shareholders will be invited. The testing will involve data collection, inspection and analysis of the product in raw and cooked state. More details will be released closer to the showcase event.

Cellular Agriculture Manufacturing Hub

The Company is also pleased to announce that 3DBT has become a project partner at the Cellular Agriculture Manufacturing Hub led by the University of Bath. This £12m UK government-funded hub is bringing together leading academic and industrial experts to accelerate and solidify the UK's position in cultured meat production. 3DBT will be working alongside other project partners and supporting them by providing its cell and tissue-enhancing City-Mix™ products.

Che Canon, Chief Executive of 3DBT, said "We are very pleased with the progress being made in our Newcastle laboratory, as we apply the findings from growing our prototype fillets and strips to refine City-Mix™ our patented animal-free cell-boosting medium, and its application. We are excited to share this scientific milestone with the industry and market in the coming months."

"Our activities are attracting attention in the industry, as demonstrated by our recent appointment as a project partner on a recently announced Cellular Agriculture Manufacturing Hub. We are looking forward to working alongside other project partners and supporting them with our cell and tissue-enhancing products and technologies."

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC
Geoff Baker - Non-Executive Director
Che Canon - Executive Director

Via SEC Newgate below

Shard Capital (Broker)
Damon Heath
Isabella Pierre

02071869927

SEC Newgate (Financial Communications)
Bob Huxford
Elisabeth Cowell
George Esmond

020 3757 6882
BSF@secnewgate.co.uk

*ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.*

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPPURWCUPWGBU